Ardsley Advisory Partners’s Aclaris Therapeutics ACRS Stock Holding History

Ardsley Advisory Partners’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,000	Closed	-$350K	–	151
2018 Q1	$350K	Buy	+20,000	New	+$424K	0.05%	115
2017 Q4	–	Sell	-20,000	Closed	-$516K	–	138
2017 Q3	$516K	Buy	20,000 +5,000	+33%	+$134K	0.07%	94
2017 Q2	$407K	Buy	+15,000	New	+$408K	0.06%	103

Other funds holding ACRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ardsley Advisory Partners's ACRS Position: Q2 2018 in Review

Ardsley Advisory Partners sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 20,000 shares — an estimated $350K sold.

Ardsley Advisory Partners first reported a position in ACRS in Q2 2017 and held it in 3 quarters. The position peaked at $516K in Q3 2017. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

Ardsley Advisory Partners reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 20,000 Aclaris Therapeutics shares in Q2 2018, an estimated $350K.
Ardsley Advisory Partners first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 3 quarters.
Ardsley Advisory Partners's Aclaris Therapeutics position peaked at $516K in Q3 2017.
96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on Ardsley Advisory Partners's 13F filing for Q2 2018, filed 14 Aug 2018.